| Autor: |
Liu Y; BeiGene (Shanghai) Co., Ltd., Shanghai, China., Ma X; BeiGene (Beijing) Co., Ltd., Beijing, China., Wu X; BeiGene (Shanghai) Co., Ltd., Shanghai, China., Hou X; BeiGene (Beijing) Co., Ltd., Beijing, China., Jin W; BeiGene (Beijing) Co., Ltd., Beijing, China., Fu L; BeiGene (Beijing) Co., Ltd., Beijing, China., Xun X; BeiGene (Shanghai) Co., Ltd., Shanghai, China., Yu Y; BeiGene (Shanghai) Co., Ltd., Shanghai, China., Shen Z; BeiGene (Beijing) Co., Ltd., Beijing, China. |
| Abstrakt: |
To evaluate the effects of gene mutations on Bruton tyrosine kinase inhibitor, zanubrutinib's effectiveness in patients with diffuse large B-cell lymphoma (DLBCL), we examined pooled data from four single-arm studies (BGB-3111-AU-003 [NCT02343120], BGB-3111-207 [NCT03145064], BGB-3111_GA101_Study_001 [NCT02569476], BGB-3111-213 [NCT03520920]; n = 121). Objective response rate (ORR) was higher, though not statistically significant, in patients with activated B-cell-like (ABC)- and unclassified DLBCL (42.9% [21/49]) versus those with germinal-center B-cell-like DLBCL (14.3% [1/7]; p = 0.15). Patients with CD79B mutations had better ORR (60%) versus patients with wild-type alleles (25.9%, p < 0.01). Higher TCL1A expression correlated with better zanubrutinib response ( p = 0.03), longer progression-free survival ( p = 0.01), and longer overall survival ( p = 0.12). TCL1A expression was higher in ABC-DLBCL ( p < 0.001) and MYD88 / CD79B -mutated subtypes ( p < 0.0001). Eighteen patients with high MYC/BCL-2 expression responded better to zanubrutinib (ORR = 61 vs. 29%, p = 0.02). Our results support assessing CD79B mutations, co-expressor DLBCL, and TCL1A expression status to identify patients with DLBCL who will benefit from zanubrutinib. |
